Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Minomic International Ltd. maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is limited to 1 distinct examiner working within 1 distinct art unit. This concentration suggests that the company's immediate patent strategy is focused on a specific technological niche or a specific application within the broader biotech sector. The lack of diversity in examiners and art units means that the company's current patent office presence is very narrow.
POHNERT, STEVEN C is identified as the busiest examiner, holding 1 busiest examiner pending action. This figure represents the total volume of pending actions for the company, meaning all current prosecution efforts are directed through this examiner. Success for the portfolio in the near term depends on navigating the specific requirements and tendencies of this art unit. Legal teams must focus their efforts on the history of POHNERT, STEVEN C and the specific standards of the 1 art unit, as the 1 pending office action constitutes the company's entire active docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POHNERT, STEVEN C | 1 | 12.4% | +18.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | POHNERT, STEVEN C | 77d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | POHNERT, STEVEN C | 77d |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18010108 | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER | POHNERT, STEVEN C | 1683 | §101§103§112DPOther | Non-Final OA | 77d | Pending | Dec 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial